Tag: movement disorders
Newronika closes €13.6 million funding round following US FDA approval for...
Newronika has successfully closed its €13.6 million Series B funding round led by a new investor, Fondazione ENEA Tech e Biomedical, with additional participation...
Abbott, Medtronic announce major CE-mark approvals for deep brain stimulation technologies
Abbott and Medtronic—two leading players in the neuromodulation space—have both announced significant CE-mark approvals relating to their respective deep brain stimulation (DBS) technologies.
Abbott announced...
Abbott launches Liberta RC deep brain stimulation system with remote programming...
Abbott recently announced that it has received approval from the US Food and Drug Administration (FDA) to launch the Liberta RC deep brain stimulation...
Revolution in neurotherapy? Spotlight on focused ultrasound at 2021 EAN congress
While focused ultrasound is by no means a brand-new innovation in the field of neurotherapy—having first been deployed in the 1950s, if not earlier,...
Long-term effectiveness of STN-DBS for Parkinson’s confirmed with 15-year follow-up study
New findings published in Neurology, the medical journal of the American Academy of Neurology (AAN), have confirmed the long-term effectiveness of deep brain stimulation...
Insightec announces approval of Exablate Neuro focused ultrasound platform in Singapore
Insightec has announced approval of its Exablate Neuro platform by the Health Sciences Authority (HSA) in Singapore. The Exablate Neuro (Exablate 4000) platform uses...
